Abstract
A number of cancer chemotherapeutics targeting the epidermal growth factor receptor (EGFR) are in development. These compounds were designed to either bind to the EGFR or inhibit signal transduction after receptor activation. Classes of inhibitory compounds include small molecules and humanized monoclonal antibodies. Many of these compounds are relatively far advanced in development. Proof of principle, with evidence of anti-tumour activity and inhibition of EGFR activation phosphorylation, has already been demonstrated in some instances. Although these new compounds offer exciting opportunities, they bring with them real challenges in terms of the selection of appropriate trial designs as well as surrogate endpoints.
Keywords: epidermal growth factor, receptor (EGFR), Tumourigenesis, Anilino-quinazoline, Quinazoline, Pyrrolo-pyrimidine, Monoclonal antibody
Current Drug Targets
Title: Epidermal Growth Factor Receptor as a Target: Recent Developments in the Search for Effective New Anti-Cancer Agents
Volume: 2 Issue: 2
Author(s): L. K. Seymour
Affiliation:
Keywords: epidermal growth factor, receptor (EGFR), Tumourigenesis, Anilino-quinazoline, Quinazoline, Pyrrolo-pyrimidine, Monoclonal antibody
Abstract: A number of cancer chemotherapeutics targeting the epidermal growth factor receptor (EGFR) are in development. These compounds were designed to either bind to the EGFR or inhibit signal transduction after receptor activation. Classes of inhibitory compounds include small molecules and humanized monoclonal antibodies. Many of these compounds are relatively far advanced in development. Proof of principle, with evidence of anti-tumour activity and inhibition of EGFR activation phosphorylation, has already been demonstrated in some instances. Although these new compounds offer exciting opportunities, they bring with them real challenges in terms of the selection of appropriate trial designs as well as surrogate endpoints.
Export Options
About this article
Cite this article as:
Seymour K. L., Epidermal Growth Factor Receptor as a Target: Recent Developments in the Search for Effective New Anti-Cancer Agents, Current Drug Targets 2001; 2 (2) . https://dx.doi.org/10.2174/1389450013348722
DOI https://dx.doi.org/10.2174/1389450013348722 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers